ACS study finds nearly four million pre-mature lung cancer deaths in U.S. averted and 76 million years of lives gained due to tobacco control
Peer-Reviewed Publication
Updates every hour. Last Updated: 14-Aug-2025 19:11 ET (14-Aug-2025 23:11 GMT/UTC)
City of Hope opens phase 1 clinical trial aiming to transform rectal cancer into a disease treatable with radiation therapy to avoid potential long-term side effects of surgery. Physician scientists will evaluate an alternative use of an investigational enzyme inhibitor, papaverine, which is hypothesized to prime regions of tumors to be more susceptible to radiation therapy
A Japanese research team has discovered a novel global cooperative phenomena of cell interactions in cervical cancer cells. Their findings suggest that the cells are metabolically connected in a functional network. The framework they used in their studies could prove useful for investigating the hidden state of a group of cells.
Iron-dependent ferroptosis, a non-apoptotic cell death mechanism, is gaining attention for its role in immune suppression. Ferroptosis, driven by excessive lipid peroxides and iron-dependent reactive oxygen species (ROS), differs from other cell death forms in its immunogenicity. It involves the regulation of the cystine/glutamate transport system xc−, with glutathione (GSH) and glutathione peroxidase 4 (GPX4) preventing toxic lipid peroxide accumulation. Ferroptosis-related factors are implicated in various diseases, including cancer and cardiovascular diseases.
A groundbreaking study has revealed a significant link between the frequency of chest x-ray referrals from GPs and earlier diagnosis and improved survival rates for lung cancer patients.
Physician-scientists Preet Chaudhary, M.D., Ph.D., and Michael Selsted, M.D., Ph.D., both from the Keck School of Medicine, have been elected as senior members of the National Academy of Inventors (NAI), an organization that recognizes inventors holding U.S. patents and promotes academic technology and innovation to benefit society. Chaudhary holds 12 allowed/issued U.S. patents, 16 allowed/issued international patents, and more than 120 pending applications. These are for next-generation treatments, genetically tailored for individual patients, that help a patient’s own immune system target multiple types of cancer—leukemias, lymphomas, multiple myeloma, and solid tumors. The overarching goal is to equip human immune cells to combat internal threats such as cancer in the same way they fend off external invaders such as viruses. Selsted has made pivotal contributions to the field of innate immunity, with innovations resulting in 60 US patents, 130 international patents, and another 80 pending applications. Selsted and his team were the first to identify and characterize theta defensins, a type of protein found only in old-world primates such as baboons and rhesus monkeys, that act as a crucial first line of defense against infection and disease. The team is developing synthetic versions of theta defensin as drug candidates for treating rheumatoid arthritis, inflammatory bowel disease, sepsis, and cancer.